Fulcrum therapeutics reports qtrly loss per share 66 cents

Fulcrum therapeutics reports recent business highlights and second quarter 2020 financial results.fulcrum therapeutics inc - on track to share topline results on primary endpoint in q1 of 2021 for redux4.fulcrum therapeutics inc - on track to initiate phase 1 trial of ftx-6058 in q4 of 2020.fulcrum therapeutics inc qtrly loss per share 66 cents.fulcrum therapeutics inc qtrly collaboration revenue $2 million.
FULC Ratings Summary
FULC Quant Ranking